US Pharma MarketingVir makes solid tumor T cell engager deal with Gilead
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes $1.79B in potential milestones. Vir shares up 78% YTD. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead.
Gilead will pay Vir $65 million upfront, with another $45 million in near-term milestones. Gilead's also paying a ...
Source: Endpoints News